Literature DB >> 8299092

A randomized study with the pineal hormone melatonin versus supportive care alone in patients with brain metastases due to solid neoplasms.

P Lissoni1, S Barni, A Ardizzoia, G Tancini, A Conti, G Maestroni.   

Abstract

BACKGROUND: Unresectable brain metastases remain an untreatable disease. Because of its antitumor cytostatic action and its anticonvulsant effect, the pineal hormone melatonin could constitute a new effective agent in the treatment of brain metastases. The current study was performed to evaluate the effect of melatonin on the survival time in patients with brain metastases due to solid neoplasms.
METHODS: The study included 50 patients, who were randomized to be treated with supportive care alone (steroids plus anticonvulsant agents) or with supportive care plus melatonin (20 mg/day at 8:00 p.m. orally).
RESULTS: The survival at 1 year, free-from-brain-progression period, and mean survival time were significantly higher in patients treated with melatonin than in those who received the supportive care alone. Conversely, steroid-induced metabolic and infective complications were significantly more frequent in patients treated with supportive care alone than in those concomitantly treated with melatonin.
CONCLUSIONS: The pineal hormone melatonin may be able to improve the survival time and the quality of life in patients with brain metastases due to solid tumors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8299092     DOI: 10.1002/1097-0142(19940201)73:3<699::aid-cncr2820730332>3.0.co;2-l

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

Review 1.  Radiotherapy and chemotherapy of brain metastases.

Authors:  R Soffietti; A Costanza; E Laguzzi; M Nobile; R Rudà
Journal:  J Neurooncol       Date:  2005-10       Impact factor: 4.130

2.  Total antioxidant capacity of plasma in asymptomatic carrier state of Neisseria meningitidis.

Authors:  J Uberos; A Molina-Carballo; G Galdo-Muñoz; A Muñoz-Hoyos
Journal:  Epidemiol Infect       Date:  2006-11-17       Impact factor: 2.451

Review 3.  Molecular mechanisms of melatonin's inhibitory actions on breast cancers.

Authors:  Sara Proietti; Alessandra Cucina; Russel J Reiter; Mariano Bizzarri
Journal:  Cell Mol Life Sci       Date:  2012-09-25       Impact factor: 9.261

4.  Intervention in the aging immune system: Influence of dietary restriction, dehydroepiandrosterone, melatonin, and exercise.

Authors:  M A Pahlavani
Journal:  Age (Omaha)       Date:  1998-10

5.  Randomized phase II trial of high-dose melatonin and radiation therapy for RPA class 2 patients with brain metastases (RTOG 0119).

Authors:  Lawrence Berk; Brian Berkey; Tyvin Rich; William Hrushesky; David Blask; Michael Gallagher; Mahesh Kudrimoti; Ronald C McGarry; John Suh; Minesh Mehta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-04-06       Impact factor: 7.038

Review 6.  Update on the role of melatonin in the prevention of cancer tumorigenesis and in the management of cancer correlates, such as sleep-wake and mood disturbances: review and remarks.

Authors:  Mariangela Rondanelli; Milena Anna Faliva; Simone Perna; Neldo Antoniello
Journal:  Aging Clin Exp Res       Date:  2013-09-18       Impact factor: 3.636

7.  Circadian function in patients with advanced non-small-cell lung cancer.

Authors:  R D Levin; M A Daehler; J F Grutsch; J Quiton; C G Lis; C Peterson; D Gupta; K Watson; D Layer; S Huff-Adams; B Desai; P Sharma; M Wallam; M Delioukina; P Ball; M Bryant; M Ashford; D Copeland; M Ohmori; P A Wood; W J M Hrushesky
Journal:  Br J Cancer       Date:  2005-11-28       Impact factor: 7.640

Review 8.  Treatment targeted at underlying disease versus palliative care in terminally ill patients: a systematic review.

Authors:  Tea Reljic; Ambuj Kumar; Farina A Klocksieben; Benjamin Djulbegovic
Journal:  BMJ Open       Date:  2017-01-06       Impact factor: 2.692

9.  Therapeutic strategies of melatonin in cancer patients: a systematic review and meta-analysis.

Authors:  Yi Wang; Pengcheng Wang; Xiaoli Zheng; Xing Du
Journal:  Onco Targets Ther       Date:  2018-11-08       Impact factor: 4.147

Review 10.  The rationale for treating uveal melanoma with adjuvant melatonin: a review of the literature.

Authors:  Anna Hagström; Ruba Kal Omar; Pete A Williams; Gustav Stålhammar
Journal:  BMC Cancer       Date:  2022-04-13       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.